Clinical Trials
75 trialsLN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
NeoTOP
Sun Yat-sen University
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
H. Lee Moffitt Cancer Center and Research Institute
BARBICAN
Queen Mary University of London
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NRG Oncology
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
University of Washington
NeoTRACT
University of Kansas Medical Center
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
SASCIA
GBG Forschungs GmbH
ToPCourT
Wake Forest University Health Sciences
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
Virginia Commonwealth University
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Cedars-Sinai Medical Center
InCITe
University of California, San Francisco
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
TELESCOPE
MedSIR
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer
Xijing Hospital
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
Memorial Sloan Kettering Cancer Center
PERCEPTION
Centre Jean Perrin
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer
Universidad Europea de Madrid
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
Harbin Medical University
Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery
M.D. Anderson Cancer Center
PDO-Mercurial
Istituti Clinici Scientifici Maugeri SpA
Onvansertib + Paclitaxel In TNBC
Dana-Farber Cancer Institute
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
SKYLINE
Institut Curie
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
Memorial Sloan Kettering Cancer Center
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
TNBC-RT2023
Centre Paul Strauss
Ribociclib and Bicalutamide in AR+ TNBC
Big Ten Cancer Research Consortium
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
M.D. Anderson Cancer Center
INSTIGO
Centre Jean Perrin
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
Rutgers, The State University of New Jersey
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Massachusetts General Hospital
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
University of Kansas Medical Center
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Massachusetts General Hospital
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Massachusetts General Hospital
NADiR
Massachusetts General Hospital
UNITY
Massachusetts General Hospital
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Lund University Hospital
Comparison of the Breast Tumor Microenvironment
Columbia University
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center